Compare Amylx Pharmaceuticals Inc (AMLX) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Gitlab Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.57 (market cap $2.64B), while Gitlab Inc trades at $41.21 (market cap $7.11B). The key difference: Gitlab Inc is far larger — about 2.7× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | GTLB | |
|---|---|---|
Market Cap | $2.64B | $7.11B |
Sector | Health | Technology |
52-Week High | $24.19 | $51.04 |
52-Week Low | $7.82 | $19.42 |
Enterprise Value | $2.39B | $5.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
GitLab (GTLB) trades at $40.98, up 0.61% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Revenue grew to $759.25M in 2025, with a high gross margin of 86.74%, but net income remains negative. Recent news highlights AI-driven product launches and Gartner leadership recognition, fueling positive sentiment.
Outlook: Growth prospects are robust due to AI integration and market position, but high valuation (P/E 521.22) and lack of profitability pose risks. Analyst consensus is mixed with a $32.92 price target, suggesting caution despite operational strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
